| 000 | 01558 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250513043723.0 | ||
| 264 | 0 | _c19950724 | |
| 008 | 199507s 0 0 eng d | ||
| 022 | _a0066-4804 | ||
| 024 | 7 |
_a10.1128/AAC.39.3.668 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGroothuis, J R | |
| 245 | 0 | 0 |
_aSafety and bioequivalency of three formulations of respiratory syncytial virus-enriched immunoglobulin. _h[electronic resource] |
| 260 |
_bAntimicrobial agents and chemotherapy _cMar 1995 |
||
| 300 |
_a668-71 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulins _xadverse effects |
| 650 | 0 | 4 | _aInfant |
| 650 | 0 | 4 | _aInfant, Newborn |
| 650 | 0 | 4 | _aInfant, Premature |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aRespiratory Syncytial Virus Infections _xprevention & control |
| 650 | 0 | 4 |
_aRespiratory Syncytial Virus, Human _ximmunology |
| 650 | 0 | 4 | _aTherapeutic Equivalency |
| 700 | 1 | _aSimoes, E A | |
| 700 | 1 | _aLehr, M V | |
| 700 | 1 | _aKramer, A A | |
| 700 | 1 | _aHemming, V G | |
| 700 | 1 | _aRodriguez, W J | |
| 700 | 1 | _aArrobio, J | |
| 700 | 1 | _aWelliver, R C | |
| 700 | 1 | _aSiber, G R | |
| 773 | 0 |
_tAntimicrobial agents and chemotherapy _gvol. 39 _gno. 3 _gp. 668-71 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1128/AAC.39.3.668 _zAvailable from publisher's website |
| 999 |
_c7793226 _d7793226 |
||